Clinical Trials in China / NCT06863441
Starting soon
Observational
The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
NCT06863441 · tracked via the Priya Life Science China tracker
Condition(s) studied
T-NK Cell Lymphoma
Study summary
The study on the value of PET imaging targeting granzyme B in predicting the efficacy and prognosis of T-NK cell lymphoma.
Eligibility
Inclusion Criteria:
1. Age \> 18 years, regardless of gender.
2. Histopathologically confirmed diagnosis of T-NK cell lymphoma.
3. Newly diagnosed and untreated patients or refractory/relapsed patients preparing to undergo immunotherapy.
4. Availability of complete clinicopathological and follow-up data.
5. Signed and dated informed consent form.
Exclusion Criteria:
1. Patients who have previously received anti-tumor therapy.
2. Patients with a history of other malignancies.
3. Incomplete clinical information or imaging data.
4. Concurrent other malignant tumors.
5. Patients with severe medical conditions deemed unsuitable for participation in this clinical study by the investigator, such as severe cardiopulmonary insufficiency or severe hepatic and renal dysfunction.
6. Poor compliance.
Primary outcome measure(s)
- Standardized uptake value (SUV) — Baseline and 7-10 days after treatment
SUV of 68Ga-grazytracer uptake on PET/CT images for tumor lesions
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School, Shanghai | Shanghai | Shanghai Municipality |
More Ruijin Hospital trials in China
Ultrasound Assessment of Isolated Distal Deep Vein Thrombosis
Active, not recruiting
Bronchoscopic Navigation Robot-guided Dye Marking-assisted Thoracoscopic Pulmonary Nodule Resection
Recruiting
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06863441 on ClinicalTrials.gov ↗ ← All trials in China